Group
JAK inhibitor
Group Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | JAK-STAT inhibitors |
| Mechanism of Action | JAK inhibitor |
| Drugs in group | Ruxolitinib |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing mechanistically (blocks RT-activated JAK/STAT3 repair/anti-apoptosis) (Hall et al., International Journal of Biochemistry & Cell Biology, 2020; Shih, Pharmacology & Therapeutics, 2022). Because JAK/STAT also mediates normal-tissue repair and hematopoiesis, a theoretical increase in in-field adverse events and additive cytopenias/immunosuppression is plausible.
The data above refer to patients treated with JAK inhibitor as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.